Results 21 to 30 of about 39,473 (264)
Low-dose levodopa protects nerve cells from oxidative stress and up-regulates expression of pCREB and CD39. [PDF]
PLoS ONE, 2014 OBJECTIVE: This study aimed to investigate the influence of low-dose levodopa (L-DOPA) on neuronal cell death under oxidative stress. METHODS: PC12 cells were treated with L-DOPA at different concentrations. We detected the L-DOPA induced reactive oxygen
Shi-Ying Zhong +5 more
doaj +1 more source
Journal of Pharmacological Sciences, 2023 The adenosine A2A receptor antagonist/inverse agonist, KW-6356 has been shown to be effective in Parkinson's disease (PD) patients as monotherapy and as an adjunct therapy to L-3,4-dihydroxyphenylalanine (L-DOPA)/decarboxylase inhibitor.
Yutaro Ohno +6 more
doaj +1 more source
Cells, 2023 Dopamine replacement therapy for Parkinson’s disease is achieved using L-DOPA or dopamine D2/3 agonists, such as ropinirole. Here, we compare the effects of L-DOPA and ropinirole, alone or in combination, on patterns of glial and microvascular reactivity
Osama F. Elabi +4 more
doaj +1 more source
Simultaneous Determination of Levodopa and Carbidopa from Fava Bean, Green Peas and Green Beans by High Performance Liquid Gas Chromatography [PDF]
Journal of Clinical and Diagnostic Research, 2013 Introduction: According to many studies, sprouted fava beans are a rich source of levo-dihydroxy phenylalanine (L-dopa) the precursor of dopamine, and they are now being investigated for use in the management of Parkinson’s disease.
Mohseni Mehran S.M., Golshani B.
doaj +1 more source
Biosensors, 2022 Levodopa (L-Dopa) is considered to be one of the most effective therapies available for Parkinson’s disease (PD) treatment. The therapeutic window of L-Dopa is narrow due to its short half-life, and long-time L-Dopa treatment will cause some side effects
Lu Fang +9 more
doaj +1 more source
Frontiers in Aging Neuroscience, 2021 BackgroundIt remains unclear why patients with young-onset Parkinson’s disease more often develop levo-dihydroxyphenylalanine (L-dopa)-induced dyskinesia (LID) and have a more severe form than patients with old-onset Parkinson’s disease. Previous studies
Haruo Nishijima +8 more
doaj +1 more source
Striatal astrocytes act as a reservoir for L-DOPA.
PLoS ONE, 2014 L-DOPA is therapeutically efficacious in patients with Parkinson's disease (PD), although dopamine (DA) neurons are severely degenerated. Since cortical astrocytes express neutral amino acid transporter (LAT) and DA transporter (DAT), the uptake and ...
Masato Asanuma +4 more
doaj +1 more source
Combination Treatment of Icariin and L-DOPA Against 6-OHDA-Lesioned Dopamine Neurotoxicity
Frontiers in Molecular Neuroscience, 2018 Until now, the dopamine (DA) precursor, L-3,4-dihydroxyphenylalanine (L-DOPA), remains the gold standard effective drug therapy for Parkinson’s disease (PD) patients.
Di-Sheng Lu +7 more
doaj +1 more source
Neurobiology of Disease, 2011 The therapeutic benefit of L-DOPA is commonly attributed to restoration of dopamine (DA) extracellular levels in the striatum of Parkinsonian patients. However, the loss of efficacy of L-DOPA after chronic use is paradoxically associated with a similar ...
Sylvia Navailles +3 more
doaj +1 more source
Frontiers in Behavioral Neuroscience, 2014 Bradykinesia (slowness of movement) and other characteristic motor manifestations of Parkinson’s disease (PD) are alleviated by treatment with L-dihydroxyphenylalanine (L-DOPA).
Stefania eSgroi +3 more
doaj +1 more source